Aims To document the haemodynamic, neurohormonal, and renal responses to Urocortin 2 (UCN2) infused in human heart failure (HF). UCN2 increased cardiac output (CO) (mean peak increments + SEM; placebo 0.3 + 0.1; LD 1.0 + 0.3; HD 2.0 + 0.2 L/min; P , 0.001) and LVEF (0.0 + 1.5; LD 5.9 + 2.1; HD 14.1 + 2.7%; P ¼ 0.001) and decreased mean arterial pressure (placebo 6.7 + 1.3; LD 11.4 + 1.7; HD 19.4 + 3.3 mmHg; P ¼ 0.001), systemic vascular resistance (SVR) (placebo 104 + 37; LD 281 + 64; HD 476 + 79 dynes s/cm 5 ; P , 0.003), and cardiac work (CW) (placebo 48 + 12; LD 66 + 22; HD 94 + 13 mmHg/L/min; P , 0.001). No significant effect on vasoconstrictor/volume-retaining neurohormones was noted. UCN2 decreased urinary volume (P ¼ 0.035) but not creatinine excretion (P ¼ 0.962). Conclusion Intravenous UCN2 in HF induced increases in CO and LVEF with falls in SVR and CW. No hormone response occurred. The role of UCN2 in circulatory regulation and its potential therapeutic application in heart disease warrant further investigation.
Introduction
Urocortin 2 (UCN2) is a vasoactive peptide belonging to the corticotrophin-releasing factor (CRF) peptide family.
1 CRF and the urocortins (UCNs) 1, 2, and 3 act through G-protein-coupled receptor subtypes, CRF 1 and CRF 2 .
2 CRF activates CRF 1 receptors, urocortin 1 (UCN1) binds to both CRF 1 and CRF 2 receptors, whereas UCN2 and urocortin 3 (UCN3) are selective agonists for the CRF 2 receptors, of which there are at least two variants, termed CRF 2(a) and CRF 2(b) . The CRF 2(a) receptor is found in high concentration in the human left ventricle, intramyocardial blood vessels, and medial layers of internal mammary arteries. [3] [4] [5] Recent reports indicate that the UCNs exert effects beyond the hypothalamo-pituitary-adrenal axis, directly upon cardiac, vascular, and vaso-humoral function in health and cardiac disease. [6] [7] [8] [9] [10] [11] UCN2 infusion in healthy humans induces increases in cardiac output (CO) and left ventricular ejection fraction (LVEF) and decreases systemic vascular resistance (SVR). 12 Activation of renin, angiotensin II, and norepinephrine occurred only with high-dose UCN2, with its more powerful haemodynamic effects in company with a modest fall-off in urine volume and sodium and potassium excretion. This parallels effects reported in normal sheep but contrasts with the pronounced suppression of volume retaining, vasoconstrictor neurohormonal systems, and augmentation of renal function observed in experimental ovine heart failure (HF). 7 In intact mice, both wild type and in the muscle-specific LIM protein-deficient HF model, UCN2 is positively inotropic, chronotropic, and lusitropic. 10 In isolated rat heart, UCN1, UCN2, and UCN3 reduce infarct size in cardiac ischaemia/reperfusion experiments. 11, 13 These reports suggest that UCN has an important role in volume/pressure homeostasis in health and heart disease.
We report the haemodynamic, echocardiographic, neurohumoral, and renal effects of UCN2 infused in human HF.
Methods Subjects
We studied eight males with stable congestive cardiac failure (six with ischaemic heart disease and two with idiopathic dilated cardiomyopathy, all with LVEF 40%, NYHA functional class II-III (seven class II and one class III]), plasma creatinine , 1.7 mg/dL (,0.15 mmol/L, range 0.08-0.11; mean 0.10 + 0.01 mmol/L), aged 43-69 (mean + SD, 61.2 + 9.8) years, weighing 78-112 (mean 97 + 11) kg, with body mass index of 26-39 (mean 33.1 + 4.3), echocardiographic LVEF of 21-39 (mean 32.9 + 5.7%), and amino terminal pro-brain natriuretic peptide (NTproBNP) of 338 + 279 pg/mL.
Subjects were taking an angiotensin-converting enzyme-inhibitor (ACE-I) (n ¼ 6) or angiotensin II receptor blocker (n ¼ 1), or both (n ¼ 1). Seven were receiving a beta-blocker, six a loop diuretic, and one spironolactone. Medications were taken at breakfast 2-3 h prior to infusion.
Study protocol
The protocol was approved by the Ethics Committee of the New Zealand Ministry of Health (Upper South B, Canterbury). Participants gave written informed consent. Human UCN2 (the 38 amino acid sequence predicted by Reyes et al.
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) was provided by Neurocrine Biosciences Inc. (San Diego, CA, USA), manufactured by Bioserv Corporation (San Diego, CA, USA). Subjects were studied using a single-blind dose-escalation design, receiving placebo and 25 and 100 mg UCN2 sequentially with a washout period of 2-5 weeks between each dose. On day 3 of metabolic diets (sodium 120 and potassium 100 mmol per day), subjects ate breakfast and presented to the study room by 0700 h. A 24 h urine collection was completed at 0800 h. The subjects fasted until lunch at 1300 h. Participants were weighed and 5 mL/kg water was given orally at 0800 h followed by 100 mL/h between 0900 and 1800 h. Subjects were seated except when standing to collect urine samples. At 0815 h, venous cannulae were placed in each forearm, one for the infusion of UCN2 or placebo, and the other for blood sampling. All subjects received vehicle placebo (dissolved in 1 mL water, then made up to 60 mL in normal saline with 50 mL administered), 25 mg UCN2 [1 mg dissolved in 6.6 mL water, then 0.2 mL of that solution made up to 60 mL in normal saline (0.5 mg/mL) with 50 mL administered], and finally 100 mg UCN2 [1 mg dissolved in 5 mL water, then 0.6 mL of that solution made up to 60 mL in normal saline (2 mg/mL) with 50 mL administered] over 1 h commencing at 0900 h.
Blood for hormone assays (drawn at 0830, 0900, 0930, 1000, 1100, 1400, and 1800 h) was collected into chilled tubes containing EDTA except for cortisol (heparin) and angiotensin II (0.125 M EDTA, 0.05 M o-phenanthroline, 2% ethanol, 0.2% neomycin sulphate, and 0.03 mg/mL enalkiren) samples. Samples were centrifuged at 48C and plasma stored at 2808C before assay for UCN2, cAMP, cyclic guanosine monophosphate (cGMP), adrenocorticotrophic hormone (ACTH), cortisol, plasma renin activity (PRA), angiotensin II, aldosterone, arginine vasopressin (AVP), NTproBNP, epinephrine, norepinephrine, endothelin 1, adrenomedullin, insulin, and ghrelin according to our published methods. 15 At the conclusion of infusions, additional samples (for UCN2 pharmacokinetics) were taken at 1005, 1010, 1015, and 1020 h. For each hormone, all samples from an individual were analysed in a single assay. Numbers of UCN2 samples were too great to fit into one assay but samples from the 25 and 100 mg UCN2 active phases were assayed together. Intra and inter-assay coefficients of variation (CVs) were all ,18.5%.
Plasma sodium (Na þ ), potassium (K þ ), creatinine, glucose, venous bicarbonate, and chloride (Cl 2 ) were measured at 0900, 1000, 1100, 1300, 1400, 1500, and 1800 h with measurement of calcium (Ca 2þ ), magnesium, phosphate, total protein, albumin, aspartate transaminase (AST), alanine transaminase (ALT), amylase, creatine kinase (CK), CK-MB fraction, and troponin T (TnT) at the 0900 and 1800 h time points.
After blood sampling, subjects stood to collect urine (0900, 1000, 1100, 1400, and 1800 h) for measurement of volume, cAMP, cGMP, Na þ , K þ , and creatinine. Systolic and diastolic blood pressure (SBP and DBP), heart rate (HR), and pulse oximetry were recorded at 0830 h, every 15 min from 0900-1100 h, then hourly until 1800 h, with an automatic sphygmomanometer and pulse oximeter (Pro 300 monitor, Dinamap, Critikon, Tampa, Florida, USA). CO was measured by the thoracic impedance method (Minnesota impedance cardiography, model 304B, Surcom Inc., Minneapolis, MN, USA) every 30 min from 0830 to 1100 h, and then hourly until 1800 h.
Echocardiography was performed 1 h before and immediately after infusions (Vivid 3 echocardiogram; General Electric, Fairfield, CT, USA). Left ventricular volume was measured in the four-chamber view, using the modified Simpson's rule. Data were stored digitally for subsequent analysis of left ventricular volumes (diastolic and systolic) and LVEF, transmitral early diastolic flow velocity (E), transmitral deceleration time (DT), early diastolic myocardial velocity (Em), diastolic myocardial velocity during atrial contraction (Am), and systolic myocardial velocity (Sm). Transmitral flow was measured by pulse wave Doppler at the mitral valve leaflet tips in the fourchamber view. Tissue Doppler myocardial velocities at the medial mitral valve annulus were measured using the machine presets. Left ventricular wall motion score index (LVWMSi) was obtained using the established 16-segment method. 16 Cardiac work (CW) was calculated as the product of CO and mean arterial pressure (MAP).
Twelve-lead electrocardiograms (ECGs) (Angilent Pagewriter 200, Angilent Technologies, Andover, MA, USA) were recorded at 0900, 1000, 1400, and 1800 h. PR interval, QRS duration, and QT interval, both uncorrected and corrected (QTc using Fridericia's method, QT/ RR 1/3 ), were assessed.
Human urocortin 2 two-site ELISA assay UCN2 was measured in a two-site chemiluminescent ELISA, using an N-terminal-directed monoclonal antibody for plate coating and a C-terminal-directed rabbit polyclonal antibody. Antisera were donated by Neurocrine Biosciences Incorporated. Mouse anti-rabbit IgG-Alkaline Phosphatase conjugate plus CSPD w substrate (Applied Biosystems, Foster City, CA, USA) were used to generate the chemiluminescent signal. Samples diluted parallel to the standard curve. Mean recovery of UCN2 was 107% at 2.43 ng/mL, 100% at 1.21 ng/ mL, and 100% at 0.61 ng/mL. The lower limit of quantitation (LOQ) was 0.3 ng/mL. The assay detection limit (upper 95% CI for the zero standard) was 0.11 ng/mL (n ¼ 36). We have used all the assay data for statistical calculations and reported 95% CI. The intra and (inter) assay CVs (n ¼ 36) were 5.0% (5.7%) at 0.68 ng/ mL, 2.8% (5.7%) at 1.34 ng/mL, and 2.8% (3.9%) at 2.45 ng/mL.
Cross-reactivities were determined by measurement of human UCN1, UCN3, and CRF at 510, 670, and 500 ng/mL, respectively, all evoking assay responses at or below the LOQ (0.3 ng/mL). UCN1 and CRF responses were also at or below the 95% CI for the zero standard.
Statistics
Data were analysed by repeated measures analysis of variance (ANOVA), using SPSS version 11.5 statistical package (SPSS Inc., Chicago, IL, USA). The significance reported for both overall dose effect and between pairs of study phases (i.e. placebo vs. 25 mg, placebo vs. 100 mg, and 25 vs. 100 mg) is the time-by-dose interaction from commencement of infusion to 1 h post-infusion unless otherwise stated. This period represents the infusion time plus four times the UCN2 half life (t 1 2 ). Where significant differences between doses were identified, paired comparisons were undertaken using Fisher's protected LSD test. UCN2 t 1 2 , metabolic clearance rate (MCR), and volume of distribution (VD) were calculated using a one-compartment model (WinNonLin Professional 3.1, Pharsight Corporation, Mountain View, CA, USA). Geometric means and 95% CI are tabulated for non-normally distributed hormone measures. Other results are presented as mean + SEM. For clarity, pooled 95% CI are displayed for the graphed hormones and pooled SEM for the graphed haemodynamics. A value of P , 0.05 was taken to indicate statistical significance.
Results

Urocortin 2 infusion
Plasma UCN2 concentrations increased in a dose-related fashion from 230 (40-420) to 1390 (1210-1590) pg/mL and 5360 (4650-6070) pg/mL with placebo and 25 and 100 mg doses, respectively (P , 0.001 for both doses compared with time-matched placebo control values). Plasma cAMP tended to increase (P ¼ 0.087; placebo compared with 100 mg dose) (Figure 1 ).
Pharmacokinetics
The t Haemodynamics and echocardiography UCN2 increased CO (maximal increments from pre-infusion levels were 0.3 + 0.1, and 1.0 + 0.3 and 2.0 + 0.2 L/min for placebo, 25 and 100 mg doses, respectively, P , 0.001 for both doses compared with placebo). Corresponding increments in HR were 1.8 + 0.8, and 4.1 + 0.9 and 6.8 + 1.0 b.p.m., P , 0.001. UCN2 decreased SBP (maximal Figure 1 Change from commencement of urocortin 2 infusion in plasma urocortin 2, cyclic adenosine monophosphate, N-terminal pro-brain natriuretic peptide, ACTH, and adrenomedullin (geometric mean and pooled 95% confidence intervals) to urocortin 2 infusion in eight male humans with mild heart failure. Urocortin 2 infusion occurred between time 0 and 1 h. 'Dose comparison' refers to overall assessment of differences between doses by ANOVA of time by dose interaction. Placebo vs. 25 mg, placebo vs. 100 mg, and 25 vs. 100 mg refer to comparison of placebo with individual active doses and between the two active doses (25 and 100 mg). Pooled 95% confidence intervals are displayed at the right upper corner in each panel.
decrements 210.6 + 1.9, and 211.9 + 2.5 and 222.6 + 4.6 mmHg, P , 0.001), DBP (25.9 + 1.3, and 211.6 + 1.6 and 218.6 + 2.7 mmHg, P , 0.001), and MAP (26.7 + 1.3, and 211.4 + 1.7 and 219.4 + 3.3 mmHg, P , 0.001). SVR fell 2104 + 37, and 2281 + 64 and 2476 + 79 dynes s/cm 5 , P ¼ 0.003, as did CW 36 + 5, and 254 + 25 and 277 + 17 L mmHg/min, P , 0.001. Sustained post-infusion decreases in SVR, CW, and arterial pressure were observed, with longer lasting and more clear-cut effects from the 100 mg compared with the 25 mg dose (Figures 2 and 3) .
With higher dose UCN2, increases in LVEF and E were observed while LVWMSi decreased (Figures 4 and 5) . No significant changes were seen in A, DT, Em, Am, Sm, or E/Em (data not shown).
Neurohormones
UCN2 infusion induced significant increases in NTproBNP, ACTH, and ADM (Figure 1) . UCN1, PRA, angiotensin II, AVP, aldosterone, epinephrine, norepinephrine, cortisol, cAMP, cGMP, ghrelin, insulin, or endothelin-1 was not significantly altered by either dose of UCN2 ( Figure 1 and Table 1 ).
Plasma biochemistry
A subtle elevation (from 0.09 + 0.01 to 0.10 + 0.01 mmol/L, P ¼ 0.045) in plasma creatinine was observed during and in the hour after the 100 mg UCN2 infusion. UCN2 infusion did not alter plasma Na þ , K þ , glucose, venous bicarbonate, Cl 2 , Ca 2þ , magnesium, phosphate, total protein, albumin, AST, ALT, amylase, CK, CK-MB, and TnT during this period (results not shown).
Urinalysis
UCN2 infusion induced no change for the period of infusion and for the subsequent hour in urinary volume, excretion of sodium, potassium, creatinine, cAMP, or cGMP. If the whole observation period was considered, UCN2 infusion induced subtle but significant dose-related decreases in urinary volume (P ¼ 0.005) and sodium excretion (P , 0.001) ( Table 2) .
Electrocardiogram
UCN2 did not change PR interval, QRS duration, and QT or QTc intervals. No arrhythmic effect of UCN2 was observed.
Observed events
All volunteers flushed during infusions of UCN2. This subsided within 2 h of the end of infusions.
Discussion
We provide the first report on UCN2 infused in human HF. Infusions of 25 and 100 mg UCN2 markedly elevated plasma UCN2, which had a t 
Haemodynamic status
We observed a dose-related increase in CO substantially secondary to decreased after-load through vasodilatation (as evidenced by decreases in SVR and flushing in all subjects at both doses) and a small increase in HR. Whether a positive inotropic effect by UCN2 also contributed to the increase in CO is uncertain. Our data cannot address this question as loading conditions and HR were not fixed. However, UCN2 has a positive inotropic effect in the isolated mouse heart, Figure 2 Cardiac output, heart rate, systemic vascular resistance, and cardiac work responses (mean and pooled standard errors) to urocortin 2 infusion in eight male humans with mild heart failure. Lunch was taken after the 4 h observations. Infusion time and statistical comparisons as per Figure 1 . Pooled SEM is displayed to upper or lower right in each panel. and in rabbit ventricular myocytes via CRF(2) receptormediated stimulation of protein kinase A (PKA). 10, 17 The CO increment is less marked than previously observed with the same dosing regimen in healthy volunteers. 12 Presumably, this reflects underlying ventricular impairment and the effects of drug therapy.
The marked decreases in SBP and DBP with only minor increments in HR reflected a vasodilator effect on a background of HF-related blunting of baroreceptor responses together with medications (e.g. beta blockade) that may also reduce reflex responses to falls in blood pressure. This contrasts with our findings in normal humans in whom there was no change in SBP, with UCN2 infusion at the same doses. It is possible that the greater increase in CO in normal subjects counterbalanced the effect of the vasodilatory response on systolic pressures, the net result being minimal change in SBP. 12 The sustained nature of the falls in arterial pressure and SVR suggests changes in intracellular signalling with longer activity than the period of elevated plasma UCN2. Multiple vasodilator mechanisms are reported for the UCNs. UCN2 acts via cAMP/PKA and p38 mitogenactivated protein kinase in rat aortic ring 18 and causes endothelium-independent vasodilatation in human internal mammary artery in vitro.
5 UCN1 induces vasodilatation in rat coronary artery via activation of PKA-dependent vascular Ca 2þ -activated K þ channels 19 (although a conflicting report suggests a PKC-mediated mechanism 20 ), and in human internal mammary artery ring smooth muscle via both endothelium-dependent and -independent mechanisms. 21 Falls in CW and SVR extended beyond the period of increased CO. The effect on calculated CW occurs predominantly postinfusion and reflects longer lasting effects on blood pressure than on HR (Figures 2 and 3) . A moiety that increases CO without increased CW over sustained intervals may have therapeutic potential in HF. However, further studies of the relative importance of vasodilation, positive inotropism, lusitropism, and chronotropism are warranted, as the balance between these effects may influence the safety profile of UCN in treating HF.
The echocardiographic findings are consistent with augmented left ventricular systolic function (with a fall in LVWMSi indicating increased contractility within viable, even if diseased, wall segments) and may reflect cardiac unloading, although, again, direct inotropic effects are also plausible. The dose-related increases in ejection fraction were substantial (approximately 6 and 15 absolute per cent for the 25 and 100 mg doses, respectively) despite the underlying myocardial dysfunction. Transmitral early diastolic flow velocity (E) increased, which may be due to greater negative pressure induced from more vigorous recoil after increased contractility, however E/Em (an index reflecting ventricular filling pressures 22 ) did not increase. Further comment on possible lusitropism, which has been noted with UCN2 exposure in both rats and rabbits, 10,17 must be reserved, as direct effects on myocardial relaxation were not measured.
Neurohormones
Given the marked haemodynamic changes, we observed remarkably little neurohormonal perturbation with UCN2 infusion. Despite 19 mmHg falls in MAP, there was no effect on PRA, aldosterone, or epinephrine, but only a small initial rise in angiotensin II and elevation in norepinephrine restricted to the higher dose infusion (Figure 1) . In normal humans infused with the same doses of UCN2, there was a smaller drop in MAP yet significant elevations in PRA and aldosterone in addition to angiotensin II and norepinephrine. 12 This may be partly explained by HF medication in that beta blockade exerts a potent inhibitory effect upon renin secretion. It is likely that the neurohormonal response to UCN2 differs between normal and HF states. 7, 8 In ovine HF, but not in normal sheep, we observed pronounced suppression of PRA, aldosterone, and epinephrine by UCN2 without elevation of norepinephrine. 7 Although this is not seen in the present work, this probably reflects the stable and relatively mild level of treated HF with only moderate haemodynamic and neurohormonal derangement compared with the extreme dysfunction of our ovine experimental HF model. Nevertheless, given the magnitude of the drop in MAP (and thus renal perfusion pressure) observed in our HF patients, a greater reninangiotensin system (RAS) activation might be expected. This suggests relative RAS suppression.
Renal function
Urine volume and urine sodium excretion were slightly reduced, although creatinine excretion (and presumably glomerular filtration) were well maintained. Although systemic levels of renin, angiotensin II, and norepinephrine were not perturbed, we cannot rule out selective intra-renal activity of these systems as the mechanism underlying these subtle changes in renal function. Currently no published data clarify this issue. There is a paucity of information on the effect of UCN2 on renal cellular activity. The possibility that the UCNs may have paracrine effects in the kidney is raised by the known secretion of UCN1 in the kidney. 23 The current findings contrast with the brisk natriuresis observed in ovine experimental HF, suggesting the natriuretic effect of UCN is only apparent when acting on a background of marked activation of the RAS and established avid sodium retention.
Increases in NTproBNP suggest an increment in cardiomyocyte distortion associated with the increased HR, LVEF, and CO. This observation was made in this HF group but not previously in normal humans and may be related to established upregulation of NP synthesis in HF. 12 The relatively subtle elevation in ACTH overall contrasts with the clear-cut stimulation seen with UCN1 in both normal subjects and in patients with HF. 15, 24 This presumably reflects the affinity of UCN2 for the peripheral, rather than central nervous system, receptor subtype. Small rises in plasma adrenomedullin were seen in response to the two active doses compared with a drop with placebo. Adrenomedullin is an endothelial product, and the observed increase may reflect increased endothelial sheer forces secondary to increased CO and regional blood flows. Adrenomedullin is a potent vasodilator. 25 There has been no literature as yet on any interaction between adrenomedullin and the UCNs, and whether UCN2 exerts a direct effect on adrenomedullin release must await further studies.
Limitations
The study sample was limited to eight patients with stable mild HF. The complexity and costs of the protocol with multiple analytes, sampled frequently on three separate occasions, necessarily limit group size. The results indicate adequate power for the detection of dose-related changes in many key haemodynamic variables. Assessment of renal responses from the current data is limited by trends towards unmatched baseline (pre-infusion) sodium excretion between study days. However, the data clearly show that the profound natriuresis previously seen in animal models of very severe decompensated HF 8 is not present. The sequential nature of dosing and the flushing response means imaging was not blinded. Because it is not possible to fix haemodynamic pre-and after-load in clinical studies of this type, we cannot precisely define the relative contributions of vasodilatory, inotropic, lusitropic, and chronotropic actions of UCN to the observed changes in blood pressure, CO, and CW.
Conclusion
UCN2 augments CO and reduces vascular resistance in humans with mild HF. The neutral neurohormonal response (which falls between the activation observed in normal humans and the profound suppression observed in severe experimental HF) despite marked haemodynamic change suggests relative RAS suppression and that the humoral response to exogenous UCN2 is dependent on the neurohumoral and haemodynamic milieu into which it is introduced. Further, natriuresis and hormone suppression may only be apparent in severe HF when neurohormonal activation is pronounced and avid sodium retention is established. Experimental and human preclinical studies to date warrant further investigation of the potentially therapeutic effects of UCN2 across a spectrum of severity of human HF.
